Arecor Therapeutics has strengthened the intellectual property around its lead concentrated insulin, AT278, with newly granted patents in Europe, the United States and India, weeks after raising fresh Capital that it says extends its cash runway to December 2027. The Patent news, announced on 15 October 2026, followed interim results and a fundraising of up to £5.13 million unveiled together on 30 September.
What the company does
Arecor is a clinical-stage biotechnology company based in Cambridge and quoted on AIM. It focuses on therapies for diabetes, obesity and other cardiometabolic diseases. Its two insulin candidates are AT278, an ultra-concentrated, ultra-rapid-acting insulin at 500 units per millilitre, and AT290, a concentrated ultra-rapid insulin at 200 units per millilitre. AT278 is designed for next-generation automated insulin delivery systems, including smaller, longer-wear pumps and fully closed-loop systems. The company is also developing an oral delivery platform for peptides, with a GLP-1 receptor agonist as its first validation target.
Latest developments
The European Patent Office and the US Patent and Trademark Office have each granted patents covering the use of AT278 in automated insulin delivery systems, extending protection to at least 2039. The Indian Patent Office granted a patent covering AT278's novel composition. Arecor said its concentrated ultra-rapid insulins are now protected by more than 30 granted patents across major markets.
The company is targeting people on intensive insulin therapy, particularly those requiring more than 100 units a day or seeking seven-day pump wear. It cites around four million people on intensive insulin therapy in the United States. In August 2026, it announced that AT278 data had been published in a peer-reviewed journal.
In its interim statement, Arecor said partnering discussions for an insulin and automated delivery combination had reached term sheet stage, and that co-development of AT278 was progressing.
Financial and Dividend picture
For the six months to 30 June 2026, Revenue fell to £0.2 million from £1.0 million a year earlier, while Research and Development costs rose to £1.9 million from £1.3 million. The loss after tax widened to £3.0 million from £2.0 million. Cash stood at £3.2 million at the end of June.
The fundraising announced on 30 September comprised a placing of new shares at 68p, which the company said represented a premium to the 60-day volume-weighted average price, together with a retail offer of up to £130,000 for existing shareholders. On full subscription the new shares would represent about 20% of the existing share capital. Proceeds are intended to strengthen the balance sheet, fund insulin development, including data generation to support a Phase 2 investigational new drug application, and support Partnership negotiations with insulin pump companies. The result of the retail offer was announced on 7 October. As a development-stage company, Arecor does not pay a dividend.
Sector and index context
Automated insulin delivery is one of the fastest-developing areas of diabetes care, with pump makers seeking insulins suited to smaller devices and longer wear times. Arecor is among the life sciences companies in the FTSE AIM All Share Index whose prospects depend heavily on securing commercial partners for their technology.
Key risks
Arecor remains loss-making and dependent on external funding, and the latest raise diluted existing holders. Term sheet discussions may not result in binding agreements. Clinical development and regulatory approval carry uncertainty, and larger insulin manufacturers and pump companies hold significant bargaining power. The fall in first-half revenue also highlights how lumpy partnership income can be.
What to watch next
Investors will watch for conversion of the partnering discussions into a signed deal, progress towards the Phase 2 application for its concentrated insulin, updates on the oral peptide platform, and full-year results for 2026.






Please wait processing your request...